Canada markets close in 4 hours 35 minutes

Alnylam Pharmaceuticals, Inc. (DUL.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
138.80+2.15 (+1.57%)
As of 08:20AM CEST. Market open.
Currency in EUR

Valuation Measures4

Market Cap (intraday) 17.70B
Enterprise Value 16.64B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)10.00
Price/Book (mrq)N/A
Enterprise Value/Revenue 9.10
Enterprise Value/EBITDA -77.29

Trading Information

Stock Price History

Beta (5Y Monthly) 0.40
52-Week Change 3-23.49%
S&P500 52-Week Change 323.57%
52 Week High 3195.40
52 Week Low 3132.95
50-Day Moving Average 3138.43
200-Day Moving Average 3158.03

Share Statistics

Avg Vol (3 month) 38
Avg Vol (10 day) 3N/A
Shares Outstanding 5126.45M
Implied Shares Outstanding 6130.1M
Float 8125.41M
% Held by Insiders 10.41%
% Held by Institutions 194.68%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin -24.08%
Operating Margin (ttm)-26.47%

Management Effectiveness

Return on Assets (ttm)-4.78%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)1.83B
Revenue Per Share (ttm)14.64
Quarterly Revenue Growth (yoy)31.20%
Gross Profit (ttm)N/A
EBITDA -228.12M
Net Income Avi to Common (ttm)-440.24M
Diluted EPS (ttm)-3.28
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.44B
Total Cash Per Share (mrq)19.37
Total Debt (mrq)2.68B
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.08
Book Value Per Share (mrq)-1.75

Cash Flow Statement

Operating Cash Flow (ttm)104.16M
Levered Free Cash Flow (ttm)146.53M